Laipac Technology has entered a partnership with UAE-based companies YAS Pharmaceuticals and Pure Health to launch the world’s first artificial intelligence (AI)-based Covid-19 antigen test system.
LooK SPOT AI COVID-19 Antigen Rapid Test System is a European CE-IVD approved smartphone-based diagnostic device with lateral flow immunoassay indicated for the qualitative detection of SARS-CoV-2 nucleocapsid protein in nasal swabs.
Laipac noted that the LooK SPOT AI Ecosystem transforms medical diagnostics, enabling early disease detection with reliable and precise results.
The test uses the nasal sample collected from 1in in the nostril with the help of AI technology and offers real-time test results within five to eight minutes. It has a sensitivity of 97.4% and a specificity of 98.3% in identifying the SARS-CoV-2 virus.
It can also identify the new UK and South African variant of the SARS-CoV-2 virus.
Laipac co-founder and CEO Diego Lai said: “LooK SPOT’s AI Algorithm has high accuracy and can identify the colour signal on tests in low positive cases when human eyes cannot, therefore, eliminating the human error and manual process done with other antigen tests available in the market.
“LooK SPOT reduces healthcare responders’ cognitive load by providing accurate test results in an easy-to-read format. LooK SPOT has been designed with a tactical edge to fight Covid-19.”
Prior to the test, the LooK COVID-19 antigen cassette can be scanned using the LooK PASS App, which is available for download in Apple or Google stores. The results will be received on smartphones within five to eight minutes.
Furthermore, negative test results provide a QR code on the app, which can be used as a pass to enter a facility, events, and gatherings, or even for transport facilities.
Though Pure Health, LooK SPOT could offer a full API integration with multiple IT and travel applications for real-time reporting.
